SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev 2001; 23: 4258.
  • 2
    Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998; 58: 4497504.
  • 3
    Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (Steroid 17alpha-hydroxylase/17,20 lyase): Similarity with the gene for P450c21. DNA 2003; 6: 43948.
  • 4
    Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 18736.
  • 5
    Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 57103.
  • 6
    Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatzl G, Madersbacher S, Marberger M, Vutuc C, Micksche M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000; 87: 4347.
  • 7
    Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston GM. CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001; 10: 9437.
  • 8
    Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20: 172731.
  • 9
    Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001; 92: 6836.
  • 10
    Chang B, Zheng SL, Isaacs SD, Wiley KE, Carpten JD, Hawkins GA, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer 2001; 95: 3549.
  • 11
    Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, Kantoff PW, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 7438.
  • 12
    Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 11307.
  • 13
    Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 6359.
  • 14
    Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, Ostrander EA. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 2437.
  • 15
    Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000; 60: 51116.
  • 16
    Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Benichou J, Xie T, Gao YT. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2000; 9: 133541.
  • 17
    Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93: 7839.
  • 18
    Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001; 10: 107782.
  • 19
    Hsing AW, Chokkalingam AP, Gao YT, Wu G, Wang X, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Chiang T, Chen YL, Stanczyk FZ, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11: 33741.
  • 20
    Goebelsman U, Bernstein GS, Gale JA, Kletzky OA, Nakamura RM, Coulson AH, Korelitz JJ. Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In: IH Lepow, R Crozier. Vasectomy: immunologic and pathophysiologic effects in animals and man. New York: Academic Press, 1979. 16575.
  • 21
    Serafini P, Ablan F, Lobo RA. 5 alpha-Reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985; 60: 34955.
  • 22
    Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Jr, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001; 10: 4217.
  • 23
    Breslow NE, Day NE. Statistical methods in cancer research, vol. I: the analysis of case-control studies. IARC Sci Publ, 1980. 5338.
  • 24
    Daniel W. Analysis of variance, In: Daniel W. Biostatistics, a foundation for analysis in the health sciences. New York: John Wiley and Sons, 1987. 273366.
  • 25
    Vendola K, Zhou J, Wang J, Bondy CA. Androgens promote insulin-like growth factor-I and insulin-like growth factor-I receptor gene expression in the primate ovary. Hum Reprod 1999; 14: 232832.
  • 26
    Berstein LM, Imyanitov EN, Gamajunova VB, Kovalevskij AJ, Kuligina ESH, Belogubova EV, Buslov KG, Karpova MB, Togo AV, Volkov ON, Kovalenko IG. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Letters 2002; 180: 4753.
  • 27
    Hsing AW, Gao YT, Streamson C Jr, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 6771.
  • 28
    Concepts and basic methods for multiple comparisons and testing: Bonferroni and Sidak methods. In: Westfall P, Tobias R, Rom D, Wolfinger R, Hochberg Y. Multiple comparisons and multiple tests using the SAS system. Cary, NC: SAS Institute, Inc., 1999. 2228
  • 29
    Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 1206.
  • 30
    Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001; 10: 1859.